Evaluation of an Intensive Intermittent‐Induction Regimen and Duration of Short‐Course Treatment for Human Immunodeficiency Virus–Related Pulmonary Tuberculosis
The DOI matches its Crossref record.
Abstract
This study examined whether adding levofloxacin to a standard four-drug regimen improved the 8-week culture response and compared effectiveness of 9 versus 6 months of intermittent therapy for human immunodeficiency virus-related pansusceptible pulmonary tuberculosis. Patients were randomized to receive either four or five drugs, the fifth being levofloxacin. Patients who completed induction therapy were randomized to complete 9 versus 6 months of intermittent therapy with isoniazid and rifampin. In the randomized induction phase, 97.3% of patients in the four-drug group and 95.8% in the five-drug group had sputum culture conversion at 8 weeks (P = 1.00). In the continuation phase, one patient (2%) assigned to 9 months and two patients (3.9%) assigned to 6 months of therapy had treatment failure/relapse (P = 1.00). In conclusion, this study showed that levofloxacin added no benefit to a highly effective, largely intermittent, four-drug induction regimen. Both 9 and 6 months of intermittent therapy were associated with low treatment failure/relapse rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Fluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
Dean, G. L., Edwards, S. G., Ives, N. J., Matthews, G., Fox, E. F., Navaratne, L., Fisher, M., Taylor, G. P., Miller, R., Taylor, C. B., et al. (2002) · AIDS · doi:10.1097/00002030-200201040-00010 · Cited by 354
Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials
Burman, W. J., Gallicano, K., & Peloquin, C. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140050-00002 · Cited by 337
Tuberculosis in HIV-infected patients: a comprehensive review
Aaron, L., Saadoun, D., Calatroni, I., Launay, O., Mémain, N., Vincent, V., Marchal, G., Dupont, B., Bouchaud, O., Valeyre, D., et al. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00758.x · Cited by 330
Metadata
- Authors
- El‐Sadr, W. M., Perlman, D. C., Matts, J. P., Nelson, E. T., Cohn, D. L., Salomon, N., Olibrice, M., Medard, F., Chirgwin, K. D., Mildvan, D., Jones, B. E., Telzak, E. E., Klein, O., Heifets, L., & Hafner, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-05
- Volume
- 26
- Issue
- 5
- Pages
- 1148-1158
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2102212813
- Cited by
- 118
- References
- 0
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of an Intensive Intermittent‐Induction Regimen and Duration of Short‐Course Treatment for Human Immunodeficiency Virus–Related Pulmonary Tuberculosis. https://app.cochat.ai/papers/10.1086/520275
- The paper
- El‐Sadr, W. M., Perlman, D. C., Matts, J. P., Nelson, E. T., Cohn, D. L., Salomon, N., Olibrice, M., Medard, F., Chirgwin, K. D., Mildvan, D., Jones, B. E., Telzak, E. E., Klein, O., Heifets, L., & Hafner, R. (1998). Evaluation of an Intensive Intermittent‐Induction Regimen and Duration of Short‐Course Treatment for Human Immunodeficiency Virus–Related Pulmonary Tuberculosis. Clinical Infectious Diseases. https://doi.org/10.1086/520275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.